Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PRCP | P42785 | 8/20 | 0.53 |
| ▸ | HPGDS | O60760 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203160 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15368454 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL749185 | 0.96 | PRCP (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL2706110 | 0.96 | CYP3A4 (0.58) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL10092430 | 0.95 | HPGDS (0.54) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL753302 | 0.95 | CYP3A4 (0.60) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL11910995 | 0.95 | CYP3A4 (0.60) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL18845571 | 0.94 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15854475 | 0.94 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL203852 | 0.93 | CYP3A4 (0.58) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9932326-B2 | Potent and selective inhibitors of hepatitis C virus | Cocrystal Pharma, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932326-B2 | Potent and selective inhibitors of hepatitis C virus | Cocrystal Pharma, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| EP-2963034-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS Pharma, LLC. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9181227-B2 | Potent and selective inhibitors of hepatitis C virus | COCRYSTAL PHARMA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181227-B2 | Potent and selective inhibitors of hepatitis C virus | COCRYSTAL PHARMA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8436036-B2 | Diaryl ethers | JANSSEN R&D IRELAND (IE) | 2013-05-07 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012027712-A2 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS PHARMA, LLC (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | CYP3A4 208/4885CYP2C9 329/4885NR1I2 413/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20120034678-A1 | Diaryl Ethers | SLC10A1, CYP2F1, UGT1A1 | CYP3A4 58/4885CYP2C9 67/4885NR1I2 65/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885NR1I2 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.